Novel Drugs Targeting Transthyretin Amyloidosis
- 750 Downloads
Transthyretin amyloidosis (ATTR) is either a hereditary disease related to a mutation in the transthyretin gene that leads to neuropathy and/or cardiomyopathy or an acquired disease of the elderly that leads to restrictive cardiomyopathy. The prevalence of this disease is higher than once thought and awareness is likely to increase amongst physicians and in particular cardiologists. Until recently there have been no treatment options for this disease except to treat the heart failure with diuretics and the neuropathy symptomatically. However, there are several emerging pharmacologic therapies designed to slow or stop the progression of ATTR. This article reviews novel therapeutic drugs that work at different points in the pathogenesis of this disease attempting to change its natural history and improve outcomes.
KeywordsTransthyretin Amyloid Amyloidosis Cardiac Cardiomyopathy Neuropathy Familial Senile Hereditary Pharmacologic Therapy Drugs
Compliance with Ethics Guidelines
Conflict of Interest
Mazen Hanna received a one-time consultant fee from Pfizer in April 2012 regarding input for the drug Tafamadis. He is also the local principal investigator of the Tafamadis Cardiomyopathy Trial and is a member of the Scientific Board for THAOS (Transthyretin Outcomes Survey), both sponsored by Pfizer.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 12.••Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–300. Comprehensive up-to date review of transthyretin cardiac amyloidosis outlining epidemiology, pathogenesis, diagnosis, and treatment. It includes a summary of emerging treatments.PubMedCentralPubMedCrossRefGoogle Scholar
- 38.•Lachmann HJ. A new era in the treatment of amyloidosis? N Engl J Med. 2013;369(9):866–8. A very insightful editorial in response to the New England Journal publication about small interfering RNA treatment in TTR amyloid. This summarizes the current issues and strategies very well.PubMedCrossRefGoogle Scholar
- 39.••Coelho T et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–29. Along with antisense oligonucleotides, this is a major breakthrough and publication in the field. Getting published in the New England Journal of Medicine has brought transthyretin amyloidosis into greater awareness amongst physicians.PubMedCrossRefGoogle Scholar
- 46.••Berk JL et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–67. This is the only randomized placebo-controlled trial in transthyretin amyloidosis that has met its primary endpoint. This landmark clincial trial will likely lead to the approval of Diflunisal for the indication of FAP.Google Scholar
- 47.••Coelho T et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92. This was the first randomized placebo-controlled trial in transthyretin amyloidosis. Although the primary endpoint was not met, the results led to the approval of Tafamdis in Europe.Google Scholar